Next Article in Journal
Radiation-Induced Lung Injury—Current Perspectives and Management
Previous Article in Journal
Cross-Cultural Adaptation of the Brazilian Portuguese-Translated Version of the Mini Sarcopenia Risk Assessment (MSRA) Questionnaire in Cancer Patients
Case Report

Adalimumab-Induced Rhupus Syndrome in a Female Patient Affected with Anti-Citrullinated Protein Antibody (ACPA)-Positive Rheumatoid Arthritis (RA): A Case Report and Review of Literature

1
Internal and Geriatric Medicine Department, Rheumatologic Outpatient Clinic, Azienda Sanitaria Locale Napoli 3 Sud, Health District No. 59, Sant’Agnello, 80065 Naples, Italy
2
Primary Care Department, Casa Della Salute “Chiaravalle Centrale”, Fragility Outpatient Clinic, Azienda Sanitaria Provinciale di Ca-tanzaro, Chiaravalle, 88064 Catanzaro, Italy
*
Author to whom correspondence should be addressed.
Clin. Pract. 2021, 11(3), 404-409; https://doi.org/10.3390/clinpract11030055
Received: 8 May 2021 / Revised: 6 June 2021 / Accepted: 17 June 2021 / Published: 1 July 2021
We report a 38-year-old female patient affected with anti-citrullinated protein antibody (ACPA)-positive rheumatoid arthritis (RA) who developed mild hemolytic anemia (Hb = 10.5 vs. >12 gr/dL), indolent oral ulceration, ANA (1:1280, homogeneous pattern), and anti-dsDNA antibody positivity following 8 months of therapy with an adalimumab biosimilar (GP2017). Rhupus syndrome was diagnosed. Replacing GP2017 with infliximab, anemia, oral ulcer, and anti-dsDNA antibodies quickly disappeared, while low-titers (1:80) ANA are still present after more than a year. The possibility that the patient suffered from rhupus rather than drug-induced lupus erythematosus associated to anti-ACPA positivity RA was discussed. To date, after a 14-month follow-up, no manifestations of LE have reappeared. To the best of our knowledge, this is the first report of adalimumab-induced rhupus. View Full-Text
Keywords: adalimumab; biosimilars; rhupus syndrome; drug-induced lupus erythematosus adalimumab; biosimilars; rhupus syndrome; drug-induced lupus erythematosus
Show Figures

Figure 1

MDPI and ACS Style

Manzo, C.; Castagna, A. Adalimumab-Induced Rhupus Syndrome in a Female Patient Affected with Anti-Citrullinated Protein Antibody (ACPA)-Positive Rheumatoid Arthritis (RA): A Case Report and Review of Literature. Clin. Pract. 2021, 11, 404-409. https://doi.org/10.3390/clinpract11030055

AMA Style

Manzo C, Castagna A. Adalimumab-Induced Rhupus Syndrome in a Female Patient Affected with Anti-Citrullinated Protein Antibody (ACPA)-Positive Rheumatoid Arthritis (RA): A Case Report and Review of Literature. Clinics and Practice. 2021; 11(3):404-409. https://doi.org/10.3390/clinpract11030055

Chicago/Turabian Style

Manzo, Ciro, and Alberto Castagna. 2021. "Adalimumab-Induced Rhupus Syndrome in a Female Patient Affected with Anti-Citrullinated Protein Antibody (ACPA)-Positive Rheumatoid Arthritis (RA): A Case Report and Review of Literature" Clinics and Practice 11, no. 3: 404-409. https://doi.org/10.3390/clinpract11030055

Find Other Styles

Article Access Map by Country/Region

1
Back to TopTop